drugset / Trial / NCT04419389
APR-246 in Combination With Acalabrutinib or Venetoclax Based Therapy in Subjects With R/R Non Hodgkin Lymphomas (NHL)
Non-randomizedParallel-groupSingle-blindTreatment
Summary
Study to determine the preliminary safety, tolerability, and pharmacokinetic (PK) profile of APR-246 in combination with either acalabrutinib or venetoclax + rituximab therapy in subjects with NHL, including relapsed and/or refractory (R/R) CLL and R/R MCL.
Timeline
- Start
- 2021-03-02
- Primary completion
- 2021-08-23
- Completion
- 2021-08-24
Outcome
Outcome not reported
Stopped (Business): “Sponsor decision”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | APR-246 | Small molecule | 4.5 g | — |
| Subject | Acalabrutinib | Small molecule | — | — |
| Subject | Rituximab | Monoclonal antibody | — | — |
| Subject | Venetoclax | Small molecule | — | — |